Literature DB >> 22453893

Clinical testing and spinal cord removal in a mouse model for amyotrophic lateral sclerosis (ALS).

René Günther1, Martin Suhr, Jan C Koch, Mathias Bähr, Paul Lingor, Lars Tönges.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder resulting in progressive degeneration of motoneurons. Peak of onset is around 60 years for the sporadic disease and around 50 years for the familial disease. Due to its progressive course, 50% of the patients die within 30 months of symptom onset. In order to evaluate novel treatment options for this disease, genetic mouse models of ALS have been generated based on human familial mutations in the SOD gene, such as the SOD1 (G93A) mutation. Most important aspects that have to be evaluated in the model are overall survival, clinical course and motor function. Here, we demonstrate the clinical evaluation, show the conduction of two behavioural motor tests and provide quantitative scoring systems for all parameters. Because an in depth analysis of the ALS mouse model usually requires an immunohistochemical examination of the spinal cord, we demonstrate its preparation in detail applying the dorsal laminectomy method. Exemplary histological findings are demonstrated. The comprehensive application of the depicted examination methods in studies on the mouse model of ALS will enable the researcher to reliably test future therapeutic options which can provide a basis for later human clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 22453893      PMCID: PMC3415170          DOI: 10.3791/3936

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  15 in total

1.  Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS).

Authors:  Sarah Knippenberg; Nadine Thau; Reinhard Dengler; Susanne Petri
Journal:  Behav Brain Res       Date:  2010-05-05       Impact factor: 3.332

2.  Onset and progression in inherited ALS determined by motor neurons and microglia.

Authors:  Séverine Boillée; Koji Yamanaka; Christian S Lobsiger; Neal G Copeland; Nancy A Jenkins; George Kassiotis; George Kollias; Don W Cleveland
Journal:  Science       Date:  2006-06-02       Impact factor: 47.728

3.  Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration.

Authors:  A M Corse; M M Bilak; S R Bilak; M Lehar; J D Rothstein; R W Kuncl
Journal:  Neurobiol Dis       Date:  1999-10       Impact factor: 5.996

4.  Optimal methods to characterize the G93A mouse model of ALS.

Authors:  Francisco J Miana-Mena; Maria J Muñoz; Gema Yagüe; Mario Mendez; Maria Moreno; Jesús Ciriza; Pilar Zaragoza; Rosario Osta
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2005-03

Review 5.  Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

Authors:  Bradley J Turner; Kevin Talbot
Journal:  Prog Neurobiol       Date:  2008-01-16       Impact factor: 11.685

6.  Design, power, and interpretation of studies in the standard murine model of ALS.

Authors:  Sean Scott; Janice E Kranz; Jeff Cole; John M Lincecum; Kenneth Thompson; Nancy Kelly; Alan Bostrom; Jill Theodoss; Bashar M Al-Nakhala; Fernando G Vieira; Jeyanthi Ramasubbu; James A Heywood
Journal:  Amyotroph Lateral Scler       Date:  2008

Review 7.  Behavioral phenotyping strategies for mutant mice.

Authors:  Jacqueline N Crawley
Journal:  Neuron       Date:  2008-03-27       Impact factor: 17.173

8.  Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase.

Authors:  Genevíève Gowing; Thomas Philips; Bart Van Wijmeersch; Jean-Nicolas Audet; Maarten Dewil; Ludo Van Den Bosch; An D Billiau; Wim Robberecht; Jean-Pierre Julien
Journal:  J Neurosci       Date:  2008-10-08       Impact factor: 6.167

9.  Assessing disease onset and progression in the SOD1 mouse model of ALS.

Authors:  Patrick Weydt; So Yon Hong; Michel Kliot; Thomas Möller
Journal:  Neuroreport       Date:  2003-05-23       Impact factor: 1.837

10.  Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis.

Authors:  Claudia Pitzer; Carola Krüger; Christian Plaas; Friederike Kirsch; Tanjew Dittgen; Ralph Müller; Rico Laage; Stefan Kastner; Stefanie Suess; Robert Spoelgen; Alexandre Henriques; Hannelore Ehrenreich; Wolf-Rüdiger Schäbitz; Alfred Bach; Armin Schneider
Journal:  Brain       Date:  2008-10-03       Impact factor: 13.501

View more
  7 in total

1.  Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils.

Authors:  Sara Breid; Maria E Bernis; Julius B Tachu; Maria C Garza; Holger Wille; Gültekin Tamgüney
Journal:  J Vis Exp       Date:  2017-04-13       Impact factor: 1.355

2.  Mass cytometry analysis of immune cells in the brain.

Authors:  Ben Korin; Tania Dubovik; Asya Rolls
Journal:  Nat Protoc       Date:  2018-01-25       Impact factor: 13.491

3.  The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice.

Authors:  René Günther; Kim-Ann Saal; Martin Suhr; David Scheer; Jan Christoph Koch; Mathias Bähr; Paul Lingor; Lars Tönges
Journal:  Front Neurosci       Date:  2014-10-07       Impact factor: 4.677

4.  FE65 and FE65L1 share common synaptic functions and genetically interact with the APP family in neuromuscular junction formation.

Authors:  Paul Strecker; Susann Ludewig; Marco Rust; Tabea A Mundinger; Andreas Görlich; Elisa G Krächan; Christina Mehrfeld; Joachim Herz; Martin Korte; Suzanne Y Guénette; Stefan Kins
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

5.  Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset.

Authors:  René Günther; Alexander Balck; Jan C Koch; Tobias Nientiedt; Michael Sereda; Mathias Bähr; Paul Lingor; Lars Tönges
Journal:  Front Pharmacol       Date:  2017-01-31       Impact factor: 5.810

6.  Brain Protease Activated Receptor 1 Pathway: A Therapeutic Target in the Superoxide Dismutase 1 (SOD1) Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Efrat Shavit-Stein; Ihab Abu Rahal; Doron Bushi; Orna Gera; Roni Sharon; Shany G Gofrit; Lea Pollak; Kate Mindel; Nicola Maggio; Yoel Kloog; Joab Chapman; Amir Dori
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

7.  Curcumin Effects on Memory Impairment and Restoration of Irregular Neuronal Distribution in the Hippocampal CA1 Region After Global Cerebral Ischemia in Male Rats.

Authors:  Leila Kamali Dolatabadi; Masoumeh Emamghoreishi; Mohammad Reza Namavar; Hamze Badeli Sarkala
Journal:  Basic Clin Neurosci       Date:  2019-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.